Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168803 · ClinicalTrials.gov registry record · Phase 1
A Study of Evacetrapib in Participants With Abnormal Cholesterol
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT02168803 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 101 participants.
The verdict
NCT02168803, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given once a day for 12, 24, and 52 weeks to participants with abnormal amounts of cholesterol and/or fat in the blood stream. Information about any side effects that may occur will also be collected. This study will also evaluate how the study drug reacts in the body when given once a day for 12, 24 and 52 weeks and how the body responds and returns to normal when the treatment is complete. The relationship between study drug and the results from the how the study drug reacts in the body may be explored, if needed.
Interventions
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168803
The ClinicalTrials.gov registry entry for NCT02168803 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evacetrapib is the first listed.
NCT02168803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168803 about?
NCT02168803 is a clinical study titled "A Study of Evacetrapib in Participants With Abnormal Cholesterol". The main purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given once a day for 12, 24, and 52 weeks to participants with abnormal amounts of cholesterol and/or fat in the blood stream. Information about any side ...
What is the current status of trial NCT02168803?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2014-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02168803?
The interventions under investigation include: Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT02168803?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.